Remegen Biosciences company information, Employees & Contact Information

RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries PR Newswire

$190M Upfront Payment: RemeGen's Breakthrough Eye Drug RC28-E Licensed to Global Vision Leader Santen Stock Titan

Investigational Telitacicept Significantly Improves Myasthenia Gravis Outcomes in Phase 3 Study NeurologyLive

China's RemeGen sells Asia rights to VEGF/FGF eye drug in $180M deal Fierce Biotech

RemeGen cools on DR5 | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Santen and RemeGen sign licence deal for retinal disease injection Pharmaceutical Technology

Vor says drug licensed from RemeGen succeeded in Sjögren’s study BioPharma Dive

RemeGen and Vor score again with telitacicept, this time in IgA nephropathy Fierce Pharma

RemeGen Announces the Acceptance of the Marketing Application of Telitaccept for the Treatment of Myasthenia Gravis in China PR Newswire

Vor Bio Enters into Exclusive Global License Agreement with RemeGen for Late-Stage Autoimmune Asset GlobeNewswire

RemeGen's Telitacicept Approved for Treatment of Myasthenia Gravis in China NeurologyLive

RemeGen's telitacicept meets the mark in phase 3 Sjögren's study in China Fierce Pharma

RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88 PR Newswire

RemeGen Announces Continued Inclusion of Telitacicept and Disitamab Vedotin in China National Reimbursement Drug List, Ensuring Continuous Accessibility of Innovative Drugs for More Patients PR Newswire

RemeGen Demonstrates Profitability to Successfully Receive Approval from the Hong Kong Stock Exchange to Upgrade Stock Short Name PR Newswire

RemeGen's RC88 Obtained FDA Fast Track Designation, Heralds New Hope for Ovarian Cancer Patients PR Newswire

First patient enrollment in the U.S. - A milestone for the global multi-center phase Ⅲ clinical trial of telitacicept for myasthenia gravis PR Newswire

RemeGen Announces Publication of Results from Two Phase II Studies for Disitamab Vedotin in Latest Issue of Journal of Clinical Oncology (JCO) PR Newswire

Remegen Announces Exciting Results of Telitacicept Phase 3 Clinical Trial for Patients with Generalized Myasthenia Gravis PR Newswire

Fierce Pharma Asia—Vor-RemeGen, Otsuka-Harbour autoimmune deals; Datroway's lung cancer nod Fierce Pharma

First-line disitamab vedotin plus toripalimab under review in China for la/mUC Urology Times

Vor Bio's surprise $4B revival deal for RemeGen's autoimmune drug triggers divergent stock reactions Fierce Pharma

RemeGen Completes USD $100 Million Plus in Funding PR Newswire

Pfizer partner RemeGen says HER2 ADC prolongs life in newly diagnosed bladder cancer Fierce Pharma

After axing 95% workforce, Vor bets $4B+ on Remegen’s telitacicept BioWorld MedTech

Remegen’s lupus drug surfaces with phase III myasthenia gravis data BioWorld MedTech

Telitacicept for autoimmune nephropathy Frontiers

Fierce Pharma Asia—J&J's $2B Fujifilm deal; Drug recalls for 3 Indian firms; RemeGen, Santen's eye med pact Fierce Pharma

China’s NMPA gives thumbs up to Remegen’s ADC targeting HER2 BioWorld MedTech

Vor and Remegen post another phase III win BioWorld MedTech

RemeGen Announces US FDA Has Granted Breakthrough Therapy Designation for Disitamab Vedotin (RC48) in Urothelial Cancer PR Newswire

Telitacicept Fast-Tracked for Systemic Lupus Erythematosus Medical Professionals Reference

RemeGen’s $4.2 billion licensing deal falls flat with investors thebambooworks.com

No respite for RemeGen as problems and losses pile up thebambooworks.com

RemeGen grabs one of the world's largest ever biotech IPOs Fierce Biotech

Seagen Strikes $2.6 Billion ADC Deal with China’s RemeGen BioSpace

FDA Grants Fast Track Designation to RemeGen's Telitacicept as a Treatment for Systemic Lupus Erythematosus PR Newswire

Potential new treatment option could mean good news for lupus patients statnews.com

RemeGen, Ltd. Announces Positive Results from Phase IIb Clinical Trial in Systemic Lupus Erythematosus MultiVu